The Orphan Drug Act and the Myth of the Exclusivity Incentive

by Robert Rogoyski, J.D.

7 Colum. Sci. & Tech. L. Rev. 4 (2006) (Published April 15, 2006)

Abstract

For more than 20 years, the marketing exclusivity provision of the Orphan Drug Act has been hailed as a key component of the incentive for the United States’ pharmaceutical industry to develop drugs for rare disorders; this is the Official Story of the ODA. In this paper, I argue that the Official Story is a myth. Rather, the real engine for the development of drugs to treat rare disorders is the patent system.

About the Author

Robert Rogoyski: J.D. cum laude, Harvard Law School, 2005.

Important Note

For proper legal citation of this document, please cite to the following URL: http://www.stlr.org/cite.cgi?volume=7&article=4. The URL that currently appears in your browser’s location toolbar is incorrect. For more information on Bluebook citation of internet sources, click here.

View in PDF

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>